secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001493152-24-046812
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals selects CHDR for Phase I/IIa trial of Ketamir-2; recruitment starts Q1 2025
--------------------------------------------------------------------------------

- Trial site: The Centre for Human Drug Research (CHDR) in Leiden, Netherlands.
- Phase I in healthy subjects: initial safety/efficacy results expected H2 2025.
- Phase IIa planned Q4 2025 in diabetic neuropathy patients; efficacy results in H1 2026.
- Will use CHDR's PainCart® technology for early pain response measurement.
- Psychoactivity assessed separately; trial leverages unique early-efficacy capability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224046812/0001493152-24-046812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224046812/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer